MTOR and breast carcinoma: Adjustment for ER status in the multivariable model did also not materially change the estimates, but adjustment for breast cancer subtype (Luminal A/Luminal B/HER2-positive/triple negative) led to slightly stronger associations of insulin with IGF1R (OR = 2.78; 95%CI:1.09–7.09; p = 0.03) and p-mTOR (OR = 3.42; 95%CI:1.43–8.17; p = 0.006), with more expression of IGF1R and p-mTOR in triple negative, and less expression in HER2 positive tumors.